title: Macrolide-resistant Mycoplasma pneumoniae in children in Taiwan.
abstract: The aim of this study was to estimate the prevalence of macrolide-resistant Mycoplasma pneumoniae in Taiwan and to compare the clinical courses of pediatric patients with macrolide-resistant (MR) M. pneumoniae and macrolide-susceptible (MS) M. pneumoniae infection. Patients were among the children admitted to Chang Gung Children's Hospital with mycoplasmal pneumonia between February and December 2011. Detection for macrolide resistance was performed after informed consent was obtained. We retrospectively reviewed medical records and compared the clinical courses of two groups of patients of 73 children enrolled into our study. The rate of macrolide resistance in M. pneumoniae was 12.3 %. Longer hospital stay was observed in the MR patients than MS patients [median, 7 days vs. 5 days (P = 0.019)]. Clinical features or radiographic or laboratory findings are not helpful to differentiate MR from MS mycoplasmal pneumonia. Early diagnosis of MR mycoplasmal pneumonia is crucial for the best management of these patients and obviates the need for extensive etiological searches of these nonresponding cases.
authors.affiliation: Division of Pediatric Pulmonology, Department of Pediatrics, Chang Gung Memorial Hospital, Taoyuan, 33305, Taiwan.
authors.forename: Han-Meng
authors.initials: HM
authors.lastname: Wu
authors.forename: Kin-Sun
authors.initials: KS
authors.lastname: Wong
authors.forename: Yhu-Chering
authors.initials: YC
authors.lastname: Huang
authors.forename: Shen-Hao
authors.initials: SH
authors.lastname: Lai
authors.forename: Kuo-Chien
authors.initials: KC
authors.lastname: Tsao
authors.forename: Ya-Jhu
authors.initials: YJ
authors.lastname: Lin
authors.forename: Tzou-Yien
authors.initials: TY
authors.lastname: Lin
mesh_terms: D000293:Adolescent; D000900:Anti-Bacterial Agents / Q000494:pharmacology* / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D004269:DNA, Bacterial / Q000032:analysis; D024881:Drug Resistance, Bacterial; D005260:Female; D005798:Genes, Bacterial / Q000235:genetics; D006760:Hospitalization; D006801:Humans; D007223:Infant; D018942:Macrolides / Q000494:pharmacology* / Q000627:therapeutic use; D008297:Male; D008826:Microbial Sensitivity Tests; D009154:Mutation; D009177:Mycoplasma pneumoniae / Q000187:drug effects* / Q000235:genetics / Q000302:isolation & purification; D010614:Pharynx / Q000382:microbiology; D011019:Pneumonia, Mycoplasma / Q000188:drug therapy / Q000382:microbiology*; D015995:Prevalence; D012338:RNA, Ribosomal, 23S / Q000235:genetics; D012189:Retrospective Studies; D013624:Taiwan / Q000453:epidemiology; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D004269:DNA, Bacterial; D018942:Macrolides; D012338:RNA, Ribosomal, 23S